When we think about human intelligence, memory is one of the first things that comes to mind. It’s what enables us to learn from our experiences, adapt to new situations, and make more informed ...
People with severe sickle cell disease (SCD) have reported significant improvements in their quality of life after receiving the approved gene-editing therapy Casgevy (exagamglogene autotemcel).
81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
Correctsequence Therapeutics’ experimental gene-editing therapy CS-101 has been used to treat a person with sickle cell disease (SCD) for the first time. Prior to treatment with CS-101, the patient — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback